https://www.selleckchem.com/products/cx-5461.html
The focus of this article is on aberrant results obtained from a validated assay with established acceptance criteria.Epidermal growth factor receptor (EGFR) inhibitors have shown poor efficacy in head and neck squamous cell carcinoma (HNSCC) with demonstrated involvement of the insulin-like growth factor-1 receptor (IGF1R) in resistance to EGFR inhibition. IGF1R activates the phosphoinositide-3-kinase(PI3K)-Akt pathway which phosphorylates proline-rich Akt substrate of 40 kDa (PRAS4 to cease mechanistic target of rapamycin (mTOR) inh
Curtir
Comentario
Compartilhar
